Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration

References

• Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598.
   PubMed Web of Science ®Google Scholar
• Gutschow C, Collard JM, Romagnoli R, Salizzoni M, Hölscher A. (2001). Denervated stomach as an esophageal substitute recovers intraluminal acidity with time. Ann Surg 233:509–514.
   Google Scholar
• Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H. (2002). Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–460.
   PubMed Web of Science ®Google Scholar
• Hussein Z, Granneman GR, Mukherjee D, Samara E, Hogan DL, Koss MA, Isenberg JI. (1993). Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 36:391–398.
   PubMed Web of Science ®Google Scholar
• Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. (2005). The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44:1179–1189.
   PubMed Web of Science ®Google Scholar
• Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. (2001). Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol 57:709–715.
   PubMed Web of Science ®Google Scholar
• Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. (1997). Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52:391–396.
   PubMed Web of Science ®Google Scholar
• Kim KA, Shon JH, Park JY, Yoon YR, Kim MJ, Yun DH, Kim MK, Cha IJ, Hyun MH, Shin JG. (2002). Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin Pharmacol Ther 72:90–99.
   PubMed Web of Science ®Google Scholar
• Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu KH, Chun JH, Hyun MH, Shin JG. (2003). Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 31:1227–1234.
   PubMed Web of Science ®Google Scholar
• Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iimori E, Sakai T, Otsubo K, Higuchi S. (1999). Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br J Clin Pharmacol 47:115–119.
   PubMed Web of Science ®Google Scholar
• Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T. (2009). Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 65:593–600.
   Google Scholar
• Landahl S, Andersson T, Larsson M, Lernfeldt B, Lundborg P, Regårdh CG, Sixt E, Skånberg I. (1992). Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 23:469–476.
   PubMedGoogle Scholar
• Marchesini G, Bua V, Brunori A, Bianchi G, Pisi P, Fabbri A, Zoli M, Pisi E. (1988). Galactose elimination capacity and liver volume in aging man. Hepatology 8:1079–1083.
   PubMed Web of Science ®Google Scholar
• McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairolero PC, Harmsen WS. (1997). Esophageal resection for cancer of the esophagus: long-term function and quality of life. Ann Thorac Surg 63:1568–1572.
   PubMed Web of Science ®Google Scholar
• Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. (2004a). Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 60:623–628.
   PubMed Web of Science ®Google Scholar
• Miura M, Tada H, Suzuki T. (2004b). Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid–phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 804: 389–395.
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Tada H, Sagae Y, Satoh S, Habuchi T, Suzuki T. (2005a). Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica 35:479–486.
   PubMed Web of Science ®Google Scholar
• Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. (2005b). Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 60:61–68.
   PubMed Web of Science ®Google Scholar
• Miura M. (2006a). Enantioselective disposition of lansoprazole and rabeprazole in human plasma. Yakugaku Zasshi 126:395–402.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Tada H, Saito M, Kagaya H, Inoue K, Sagae Y, Kanno S, Ishikawa M, Habuchi T, Suzuki T. (2006b). Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther 44:605–613.
   Google Scholar
• Miura M, Inoue K, Satoh S, Itoh Y, Kagaya H, Tada H, Tanaka Y, Habuchi T, Suzuki T. (2007). Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. Clin Drug Investig 27:251–258.
   PubMed Web of Science ®Google Scholar
• Miura M, Motoyama S, Hinai Y, Niioka T, Hayakari M, Ogawa JI, Suzuki T. (2010). Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration. Chirality 22:635–640.
   Google Scholar
• Nagaya H, Satoh H, Maki Y. (1990). Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289–1295.
   PubMed Web of Science ®Google Scholar
• Niioka T, Miura M, Uno T, Yasui-Furukori N, Hayakari M, Tateishi T, Suzuki T. (2008). Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. Eur J Clin Pharmacol 64:503–509.
   PubMed Web of Science ®Google Scholar
• Niioka T, Uno T, Sugimoto K, Sugawara K, Hayakari M, Tateishi T. (2007). Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol 63:1031–1038.
   Google Scholar
• Okuyama M, Motoyama S, Maruyama K, Sasaki K, Sato Y, Ogawa J. (2008). Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy. World J Surg 32:246–254.
   Google Scholar
• Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. (2001). Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364:551–557.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805–816.
   PubMed Web of Science ®Google Scholar
• Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P. (1995). Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 47:410–418.
   PubMed Web of Science ®Google Scholar
• Schmidt CE, Bestmann B, Küchler T, Schmid A, Kremer B. (2004). Quality of life associated with surgery for esophageal cancer: differences between collar and intrathoracic anastomoses. World J Surg 28:355–360.
   PubMedGoogle Scholar
• Shibuya S, Fukudo S, Shineha R, Miyazaki S, Miyata G, Sugawara K, Mori T, Tanabe S, Tonotsuka N, Satomi S. (2003). High incidence of reflux esophagitis observed by routine endoscopic examination after gastric pull-up esophagectomy. World J Surg 27:580–583.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738.
   PubMed Web of Science ®Google Scholar
• Yuasa N, Sasaki E, Ikeyama T, Miyake H, Nimura Y. (2005). Acid and duodenogastroesophageal reflux after esophagectomy with gastric tube reconstruction. Am J Gastroenterol 100:1021–1027.
   PubMed Web of Science ®Google Scholar
• Watts PJ, Illum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm 23: 893–913.
   Web of Science ®Google Scholar
• Woodhouse KW, Wynne HA. (1988). Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 15:287–294.
   PubMed Web of Science ®Google Scholar
• Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. (1989). The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9:297–301.
   PubMed Web of Science ®Google Scholar